TSIs PUREFLEX USP Approved

MISSOULA, Mont.—TSI Health Sciences announced its PUREFLEX Chondroitin Sulfate Sodium ingredients were approved as meeting the requirements of the U.S. Pharmacopeia’s (USP) Ingredient Verification Program. The approval process included a GMP (good manufacturing practice) audit of TSI’s wholly-owned TSI-Jiangyin Pharmaceutical Co. Ltd. chondroitin sulfate manufacturing facility, as well as a review of quality control documentation and laboratory evaluation of ingredient samples.

“TSI remains committed to providing our clients with pure, consistent and safe ingredients,” said Larry Kolb, president, U.S. operations, for TSI (www.tsiinc.com). “We wanted to validate our industry-leading quality systems by inviting a well-known and respected third-party organization to audit our facilities and confirm the quality of our ingredients.”